Daniel Auclair, PhD

Chief Scientific Officer
Dr. Daniel Auclair, who managed the MMRF Multiple Myeloma Genomics Initiative from 2007-2010, has rejoined the company after three years at the Broad Institute of MIT and Harvard.As senior leader in the Cancer Program at the Broad Institute, Dr. Auclair was involved with a wide range of academic and industry collaborations centered around cancer genomics and personalized medicine.Prior to this, he spent a decade in the pharmaceutical industry, most notably at Bayer Healthcare where he led a number of cancer drug discovery efforts.Dr. Auclair has been involved in cancer genomics efforts and drug discovery for more than 20 years. He has been honored as one of the 2017 PharmaVOICE 100. The PharmaVOICE 100 is an annual list of inspirational and innovative individuals recognized for their positive contributions to the life-sciences industry. He has been recognized for his ability to act as a “bridge across the Cancer Archipelago” fostering collaboration in myeloma advancements among academia, government agencies and pharma companies.Dr. Auclair holds graduate and post-graduate degrees in Biochemistry and Nutrition from the University of Montreal and conducted postdoctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Center.